David Fitz-Patrick

Endocrinology

1585 Kapiolani Blvd Ste 1500
Honolulu, HI 96814

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Journal: Vaccines

Published: July 02, 2026

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.

Journal: Infectious diseases and therapy

Published: January 23, 2026

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.

Journal: The New England journal of medicine

Published: November 19, 2025

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.

Journal: The New England journal of medicine

Published: November 05, 2025

Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old.

Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 06, 2025

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 06, 2025

Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial.

Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial.

Journal: Respiratory investigation

Published: March 06, 2024

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: February 10, 2024

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Journal: Diabetes, obesity & metabolism

Published: December 13, 2023

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.

Journal: Vaccine

Published: February 01, 2023

Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.

Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.

Journal: The New England journal of medicine

Published: January 18, 2023

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.

Journal: The New England journal of medicine

Published: March 23, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026